select a format

Single User License
USD 2000 INR 128320
Site License
USD 4000 INR 256640
Corporate User License
USD 6000 INR 384960

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Systemic-Onset Juvenile Idiopathic Arthritis Still Disease-Pipeline Review, H1 2016

Systemic-Onset Juvenile Idiopathic Arthritis Still Disease-Pipeline Review, H1 2016


  • Products Id :- GMDHC8173IDB
  • |
  • Pages: 141
  • |
  • June 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Pipeline Review, H1 2016', provides an overview of the Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)

The report reviews pipeline therapeutics for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) therapeutics and enlists all their major and minor projects

The report assesses Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) Overview 10

Therapeutics Development 11

Pipeline Products for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Overview 11

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Therapeutics under Development by Companies 12

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Products under Development by Companies 17

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Companies Involved in Therapeutics Development 19

AbbVie Inc. 19

Alteogen Inc. 20

Biocon Limited 21

Coherus BioSciences, Inc. 22

Epirus Biopharmaceuticals, Inc. 23

Johnson & Johnson 24

Mabion SA 25

Marathon Pharmaceuticals, LLC 26

Momenta Pharmaceuticals, Inc. 27

Mycenax Biotech Inc. 28

Novartis AG 29

Oncobiologics, Inc. 30

Oncodesign SA 31

Panacea Biotec Limited 32

Pfizer Inc. 33

Sandoz International GmbH 34

Swedish Orphan Biovitrum AB 35

Therapeutic Proteins International, LLC 36

UCB S.A. 37

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Therapeutics Assessment 38

Assessment by Monotherapy Products 38

Assessment by Target 39

Assessment by Mechanism of Action 41

Assessment by Route of Administration 43

Assessment by Molecule Type 45

Drug Profiles 47

abatacept-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

abatacept biosimilar-Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

ABT-122-Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

adalimumab biosimilar-Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

adalimumab biosimilar-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

adalimumab biosimilar-Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

adalimumab biosimilar-Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

adalimumab biosimilar-Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

adalimumab biosimilar-Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

adalimumab biosimilar-Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

adalimumab biosimilar-Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

adalimumab biosimilar-Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

adalimumab biosimilar-Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

adalimumab biosimilar-Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

anakinra (recombinant)-Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

canakinumab-Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

certolizumab pegol-Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

deflazacort-Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

etanercept biosimilar-Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

etanercept biosimilar-Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

etanercept biosimilar-Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

etanercept biosimilar-Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

etanercept biosimilar-Drug Profile 92

Product Description 92

Mechanism Of Action 92

R&D Progress 92

etanercept biosimilar-Drug Profile 95

Product Description 95

Mechanism Of Action 95

R&D Progress 95

golimumab-Drug Profile 96

Product Description 96

Mechanism Of Action 96

R&D Progress 96

methotrexate-Drug Profile 104

Product Description 104

Mechanism Of Action 104

R&D Progress 104

Small Molecules to Inhibit RIP2 for Polyarthritis, Gastrointestinal Disorders and Rheumatoid Arthritis-Drug Profile 105

Product Description 105

Mechanism Of Action 105

R&D Progress 105

tocilizumab biosimilar-Drug Profile 106

Product Description 106

Mechanism Of Action 106

R&D Progress 106

tocilizumab biosimilar-Drug Profile 107

Product Description 107

Mechanism Of Action 107

R&D Progress 107

tocilizumab biosimilar-Drug Profile 108

Product Description 108

Mechanism Of Action 108

R&D Progress 108

tofacitinib citrate-Drug Profile 109

Product Description 109

Mechanism Of Action 109

R&D Progress 109

upadacitinib tartrate-Drug Profile 121

Product Description 121

Mechanism Of Action 121

R&D Progress 121

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Dormant Projects 123

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Discontinued Products 124

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Product Development Milestones 125

Featured News & Press Releases 125

May 27, 2016: Simponi Receives CHMP Positive Opinion For Treatment Of Polyarticular Juvenile Idiopathic Arthritis 125

Apr 21, 2016: European patent granted on new formulation of Kineret (anakinra) 126

Mar 23, 2016: Sobi to initiate clinical development programs in acute gout and Still disease, and receives US patent on new formulation for Kineret (anakinra) 126

Aug 19, 2015: Kineret receives Australian regulatory approval for use in Systemic Juvenile Idiopathic Arthritis 127

Feb 12, 2015: ONS-3010 (Humira/Adalimumab Biosimilar) Meets Primary Endpoints In First Clinical Study 127

Sep 03, 2013: Novartis receives EU approval for Ilaris in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis 127

Jul 25, 2013: CHMP Adopts Positive Opinion For Novartis's Ilaris 129

May 10, 2013: Novartis's Ilaris Receives Approval From FDA For Treatment Of Active Systemic Juvenile Idiopathic Arthritis 130

Dec 19, 2012: Novartis's ACZ885 Significantly Relieves Symptoms In Patients With Serious Form Of Childhood Arthritis In Phase III Trials 131

Nov 08, 2012: Bristol-Myers Squibb To Present New Investigational Data On Orencia At 2012 American College Of Rheumatology Annual Scientific Meeting 133

Jun 06, 2012: Novartis Announces New Data From Two Trials Of ACZ885 At Annual Congress Of EULAR 2012 134

Nov 16, 2011: Novartis Study Shows ACZ885 Provides Substantial Symptom Relief In 84% Of Patients With Most Serious Form Of Childhood Arthritis 136

Nov 07, 2011: Novartis's Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use In 45% Of Patients With Serious Form Of Childhood Arthritis 137

Sep 16, 2011: Novartis Study Says ACZ885 Provided Substantial Symptom Relief In 84% Of Patients With Childhood Arthritis 138

Appendix 140

Methodology 140

Coverage 140

Secondary Research 140

Primary Research 140

Expert Panel Validation 140

Contact Us 140

Disclaimer 141

List of Figures

Number of Products under Development for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), H1 2016 11

Number of Products under Development by Companies, H1 2016 12

Comparative Analysis by Late Stage Development, H1 2016 14

Comparative Analysis by Early Stage Products, H1 2016 16

Assessment by Monotherapy Products, H1 2016 38

Number of Products by Top 10 Targets, H1 2016 39

Number of Products by Stage and Top 10 Targets, H1 2016 39

Number of Products by Top 10 Mechanism of Actions, H1 2016 41

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 41

Number of Products by Routes of Administration, H1 2016 43

Number of Products by Stage and Routes of Administration, H1 2016 43

Number of Products by Molecule Types, H1 2016 45

Number of Products by Stage and Molecule Types, H1 2016 45

List of Tables

Number of Products under Development for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), H1 2016 11

Number of Products under Development by Companies, H1 2016 13

Comparative Analysis by Late Stage Development, H1 2016 14

Comparative Analysis by Clinical Stage Development, H1 2016 15

Comparative Analysis by Early Stage Development, H1 2016 16

Products under Development by Companies, H1 2016 17

Products under Development by Companies, H1 2016 (Contd..1) 18

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Pipeline by AbbVie Inc., H1 2016 19

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Pipeline by Alteogen Inc., H1 2016 20

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Pipeline by Biocon Limited, H1 2016 21

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Pipeline by Coherus BioSciences, Inc., H1 2016 22

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Pipeline by Epirus Biopharmaceuticals, Inc., H1 2016 23

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Pipeline by Johnson & Johnson, H1 2016 24

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Pipeline by Mabion SA, H1 2016 25

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Pipeline by Marathon Pharmaceuticals, LLC, H1 2016 26

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Pipeline by Momenta Pharmaceuticals, Inc., H1 2016 27

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Pipeline by Mycenax Biotech Inc., H1 2016 28

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Pipeline by Novartis AG, H1 2016 29

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Pipeline by Oncobiologics, Inc., H1 2016 30

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Pipeline by Oncodesign SA, H1 2016 31

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Pipeline by Panacea Biotec Limited, H1 2016 32

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Pipeline by Pfizer Inc., H1 2016 33

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Pipeline by Sandoz International GmbH, H1 2016 34

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Pipeline by Swedish Orphan Biovitrum AB, H1 2016 35

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Pipeline by Therapeutic Proteins International, LLC, H1 2016 36

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Pipeline by UCB S.A., H1 2016 37

Assessment by Monotherapy Products, H1 2016 38

Number of Products by Stage and Target, H1 2016 40

Number of Products by Stage and Mechanism of Action, H1 2016 42

Number of Products by Stage and Route of Administration, H1 2016 44

Number of Products by Stage and Molecule Type, H1 2016 46

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Dormant Projects, H1 2016 123

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)-Discontinued Products, H1 2016 124

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc.

Alteogen Inc.

Biocon Limited

Coherus BioSciences, Inc.

Epirus Biopharmaceuticals, Inc.

Johnson & Johnson

Mabion SA

Marathon Pharmaceuticals, LLC

Momenta Pharmaceuticals, Inc.

Mycenax Biotech Inc.

Novartis AG

Oncobiologics, Inc.

Oncodesign SA

Panacea Biotec Limited

Pfizer Inc.

Sandoz International GmbH

Swedish Orphan Biovitrum AB

Therapeutic Proteins International, LLC

UCB S.A.

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) Therapeutic Products under Development, Key Players in Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) Therapeutics, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) Pipeline Overview, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) Pipeline, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com